Stonepine Capital Management LLC Acquires New Stake in Y-mAbs Therapeutics, Inc. $YMAB

Key Points

• Stonepine Capital Management LLC acquired a new stake in Y-mAbs Therapeutics, purchasing 131,160 shares valued at approximately $581,000, representing about 0.29% ownership of the company.
• Several institutional investors have recently increased their positions in Y-mAbs, with 70.85% of the stock now owned by hedge funds and other institutions, indicating strong interest in the company.
• Y-mAbs Therapeutics faced negative analyst ratings, with several firms downgrading their ratings and setting a target price of $8.60, reflecting a pessimistic outlook on the stock.

Stonepine Capital Management LLC acquired a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 131,160 shares of the company's stock, valued at approximately $581,000. Stonepine Capital Management LLC owned about 0.29% of Y-mAbs Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers grew its position in Y-mAbs Therapeutics by 4.8% in the 1st quarter. Rhumbline Advisers now owns 53,909 shares of the company's stock valued at $239,000 after buying an additional 2,457 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Y-mAbs Therapeutics by 12.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company's stock valued at $179,000 after buying an additional 2,545 shares during the last quarter. Jump Financial LLC boosted its position in shares of Y-mAbs Therapeutics by 14.1% during the 1st quarter. Jump Financial LLC now owns 38,079 shares of the company's stock worth $169,000 after purchasing an additional 4,699 shares in the last quarter. Brooklyn Investment Group boosted its position in shares of Y-mAbs Therapeutics by 4,563.8% during the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after purchasing an additional 5,796 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after purchasing an additional 6,131 shares in the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Jones Trading lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. HC Wainwright restated a "neutral" rating and set a $8.60 target price (down from $11.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, August 6th. Cantor Fitzgerald set a $8.60 target price on shares of Y-mAbs Therapeutics and gave the stock a "neutral" rating in a research report on Tuesday, August 5th. Morgan Stanley set a $8.60 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 5th. Finally, Canaccord Genuity Group lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and decreased their target price for the stock from $26.00 to $8.60 in a research report on Tuesday, August 5th. Eight investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of "Reduce" and a consensus price target of $9.62.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB opened at $8.53 on Friday. The company has a market capitalization of $387.60 million, a PE ratio of -17.06 and a beta of 0.57. Y-mAbs Therapeutics, Inc. has a 52-week low of $3.55 and a 52-week high of $16.11. The stock has a fifty day simple moving average of $5.66 and a 200-day simple moving average of $5.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.20. The business had revenue of $19.52 million during the quarter, compared to the consensus estimate of $18.40 million. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%. As a group, equities analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.